Evaluation of a protease activation mutant of Sendai virus as a potent live vaccine.
A protease activation mutant of Sendai virus, TR-5, was investigated as a candidate for a live vaccine. Vaccination with TR-5 which had been activated by chymotrypsin beforehand (active TR-5) elicited protective immunity against otherwise lethal challenge infection with wild-type Sendai virus in DBA/2, C3H and ICR strains of mice. Less of the active TR-5 was required to confer protection on mice compared with an ordinary ether-inactivated Sendai virus vaccine (split vaccine). The protective immunity elicited by TR-5 lasted longer and the booster effect was more prominent compared to the split vaccine. No seroconversion was observed with contact mice when housed in a cage with mice vaccinated with the active TR-5. The overall results show that the active TR-5 is an effective and safe live vaccine of Sendai virus in mice.